Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G. De Petro is active.

Publication


Featured researches published by G. De Petro.


Oncogene | 2012

Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.

Annalisa Petrelli; Andrea Perra; K. Schernhuber; Marilisa Cargnelutti; Alessandro Salvi; Cristina Migliore; Elena Ghiso; Anna Benetti; Sergio Barlati; Giovanna M. Ledda-Columbano; Nazario Portolani; G. De Petro; Amedeo Columbano; Silvia Giordano

MicroRNAs (miRNAs) have an important role in a wide range of physiological and pathological processes, and their dysregulation has been reported to affect the development and progression of cancers, including hepatocellular carcinoma (HCC). However, in the plethora of dysregulated miRNAs, it is largely unknown which of them have a causative role in the hepatocarcinogenic process. In the present study, we first aimed to determine changes in the expression profile of miRNAs in human HCCs and to compare them with liver tumors generated in a rat model of chemically induced HCC. We found that members of the miR-100 family (miR-100, miR-99a) were downregulated in human HCCs; a similar downregulation was also observed in rat HCCs. Their reduction was paralleled by an increased expression of polo like kinase 1 (PLK1), a target of these miRNAs. The introduction of miR-100 in HCC cells impaired their growth ability and their capability to form colonies in soft agar. Next, we aimed at investigating, in the same animal model, if dysregulation of miR-100 and PLK1 is an early or late event along the multistep process of hepatocarcinogenesis. The obtained results showed that miR-100 downregulation (i) is already evident in very early preneoplastic lesions generated 9 weeks after carcinogenic treatment; (ii) is also observed in adenomas and early HCCs; and (iii) is not simply a marker of proliferating hepatocytes. To our knowledge, this is the first work unveiling the role of a miRNA family along HCC progression.


Tumor Biology | 2007

RNA Interference against Urokinase in Hepatocellular Carcinoma Xenografts in Nude Mice

Alessandro Salvi; Bruna Arici; A Alghisi; Sergio Barlati; G. De Petro

The serine protease urokinase-type plasminogen activator (u-PA) is overexpressed in hepatocellular carcinoma (HCC) and its expression level is inversely correlated with the patients’ survival. The purpose of this study was to examine the effects of vector-based RNA interference (RNAi) of u-PA on the growth of human HCC xenografts in nude mice in order to investigate the role of u-PA in human HCC. Our results showed that the subcutaneous injection of small interfering RNAs (siRNA) u-PA SKHep1C3 stable transfected cells (pS siRNA u-PA) led to a growth delay in xenograft development, compared to those generated from empty vector; the molecular characterization of nodules (carried out by PCR, RT-PCR and immunohistochemical analysis) revealed the presence of plasmid DNA, the u-PA gene expression knockdown, at both mRNA and protein levels, giving evidence of a long-term and target-specific inhibition by vector-based RNAi 11 weeks after cell inoculation. We further studied the effects of u-PA downmodulation on extracellular matrix (ECM) proteins evaluating the expression and organization of fibronectin (FN; one of the main ECM proteins). Immunohistochemical and immunofluorescence analysis of FN revealed FN fibrils in pS siRNA u-PA xenografts and in pS siRNA u-PA cells, thus identifying the FN fibril organization as a downstream effect of u-PA knockdown in this system.


Fibrinolysis and Proteolysis | 1993

Interaction of Tissue-type Plasminogen Activator with Fibronectin and Fibronectin Fragments

Eleonora Marchina; G. De Petro; Sergio Barlati

Abstract In this paper we present data on the interaction, in solution, of the tissue-type plasminogen activator (t-PA) with fibronectin (FN) and its degradation products (FNdp). A cross radial caseinolytic assay (CRACA) was developed for the evaluation of the effect of the FN and/or FNdp on t-PA and urokinase plasminogen activator (u-PA) activity. A directional caseinolysis was observed when t-PA or u-PA were tested in the proximity of FNdp; no directionality was observed when intact FN or BSA were used. After incubation of t-PA, but not u-PA, with FNdp, PA activity at 170, 150, 100 and 30 kDa was detected by SDS-PAGE followed by zymography. The incubation of intact FN with t-PA gives rise to two forms of 500 and 150 kDa after prolonged incubation of the zymograms; no higher MW forms appear when u-PA substitutes t-PA. The immunoblotting analysis of the mixtures of t-PA and FN or FNdp with anti-t-PA or anti-FN sera showed that intact FN and some of its fragments interact with t-PA, giving rise to complexes recognized by both antisera and resistant to SDS-PAGE. Similar complexes are also evident, in vivo, in biological fluids like human plasma cryoprecipitates (cryos).


Fibrinolysis and Proteolysis | 1987

Characterisation of fibronectin fragments and plasminogen activators released by RSV-transformed cells

G. De Petro; Sergio Barlati

Abstract In the present study, we followed qualitatively the release of fibronectin/s (FNs) and of plasminogen activators (PAs) into the serum-free medium of normal and Rous sarcoma virus (RSV) transformed chicken embryo fibroblasts (CEF). It has been found by Western blotting analysis that RSV transformed cells release into the medium intact FN and FN peptides with a Mr ranging between 230 and I10 kDa while uninfected cells and cells infected by NY68 and PAI (temperature sensitive, ts, mutants for transformation), grown at the restrictive temperature for transformation (41°C), release mainly intact FN. The zymographic analysis of the PAs released by normal and transformed cells showed that transformed cells release into the medium a set of PA forms with Mr ranging between 180 and 43kDa while uninfected cells or cells infected with NY68 or PA1 grown at 41°C do not release or release only the 43 kDa form respectively. The analysis of the PAs present in the extracts of uninfected or PAI and NY68 infected cells, grown at 35° or 41°C, revealed mainly the presence of the 43 kDa form.


International Journal of Cancer | 1984

Tissue type plasminogen activator, but not urokinase, exerts transformation-enhancing activity.

G. De Petro; Tapio Vartio; Eeva-Marjatta Salonen; Antti Vaheri; Sergio Barlati


International Journal of Cancer | 1980

Inhibition of Rous sarcoma-virus-induced transformation by proteins involved in blood coagulation.

G. De Petro; A. Brega; P. Mignatti; S. Barlati


Neoplasia | 2009

RET/PTC-1-driven transformation and pro-invasive phenotype of human thyrocytes depend on MET induction and alpha-catenin nuclear translocation

Giuliana Cassinelli; Enrica Favini; Debora Degl'Innocenti; Alessandro Salvi; G. De Petro; Ma Pierotti; Franco Zunino; G Borrello; Cinzia Lanzi


Fibrinolysis and Proteolysis | 1994

Phosphorylation of plasminogen activators

S. Barlati; C. Bona; G. De Petro


Fibrinolysis and Proteolysis | 1994

Plasminogen activators as growth factorsof human fibroblasts

G. De Petro; Alessandro Copeta; S. Barlati


Fibrinolysis and Proteolysis | 1994

RT-PCR detection of u-PA and t-PA mRNAs: Molecular markers for hepatocellular carcinoma

Daniela Tavian; G. De Petro; N. Mounir Nasir; Nazario Portolani; Stefano Maria Giulini; S. Barlati

Collaboration


Dive into the G. De Petro's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A Alghisi

University of Brescia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge